Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1

Conditions

Multiple Myeloma 1Leukemia, Plasma Cell 1

Interventions

venetoclax 73Specimen Handling 66Cyclophosphamide 58Cytarabine 50Biopsy 49fludarabine 42Azacitidine 37Rituximab 28fludarabine phosphate 21blinatumomab 20Methotrexate 20Magnetic Resonance Spectroscopy 20Daunorubicin 20Vincristine 19Prednisone 18ibrutinib 16Injections 16Dexamethasone 16decitabine and cedazuridine drug combination 15Whole-Body Irradiation 15Tacrolimus 14Melphalan 14Doxorubicin 14Busulfan 14obinutuzumab 13acalabrutinib 13Mycophenolic Acid 13Granulocyte Colony-Stimulating Factor 13merphos 12Mercaptopurine 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
incomplete Freund's adjuvant × Other hematologic neoplasm × 30 days × Clear all
NCT02334865 2026-05-15

SVN53-67/M57-KLH Peptide Vaccine in Treating Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance Therapy

Roswell Park Cancer Institute

Phase 1 Active not recruiting
18 enrolled
Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡